In Sickness and in Health

In 2005, right after the release of the first Crosstalks publication ‘How Open is the Future?’, Crosstalks started developing a project aiming at an open and interdisciplinary dialogue between all stakeholders in health care. Through a series of introductory workshops, we explored the future role, price setting, access to and added value of medicines. An accompanying committee was set up and a three-year project was defined, funded by unconditional grants from Astra Zeneca Foundation, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, UCB and Vrije Universiteit Brussel. The project started officially in 2006 with a first congress and a series of thematic brainstorms and workshops to which all stakeholders were invited.

The ambitious aim was to establish non-mediated and constructive dialogues beyond all the disciplines and organizations involved focusing on the future role and added value of medicines. In parallel, we wanted to construct, gradually, a culture of exchange towards a sustainable and efficient health care. Thus the project set out from a bottom-up and open dialogue between universities, industry, sickness funds, health care providers, physicians, pharmacists, knowledge centers, professional health organizations and policy makers. This cross-disciplinary approach is key to give an incentive to an integrated and a more cost-balanced and qualitative cure and care.

Year: 2009 Languages: English Number of pages: 300 Binding: soft cover ISBN: 9054875496 Price: 30 €

IN SICKNESS AND IN HEALTH. The Future of Medicine: Added Value and Global Access.

Table of contents
Acknowledgements
Prologue
Table of contents

PART ONE: UNMET NEEDS

1. The future of health care – A global perspective
Tikki Pangestu, Director Research Policy & Cooperation (RPC/EIP), World Health Organization
2. Unmet medical needs: Only cooperation between all partners will lead to solutions
Paul Stoffels, Company Group Chairman Johnson & Johnson Pharmaceutical Research & Development/Chairman of Tibotec
3. Access to innovative medicines and orphan drugs
Alain Dupont, Dean of the Faculty of Pharmacy and Medicine, Vrije Universiteit Brussel
4. The increasing need for independent research
Silvio Garattini, Founder and Director of the Mario Negri Institute for Pharmacological Research, Milano
5. The cost and added value of personalized medicine
Jacques De Grève, Head of the Medical Oncology Dept UZ Brussel
6. Breaking the deadlock of budgetary autism: What are the paradigms for future health care organization in Belgium?
Marc De Vos, General Director of the Itinera Institute & Brieuc Van Damme, Junior Fellow Itinera Institute

PART TWO: SHARED RESPONSABILITY

7. Willingness to pay and solidarity
Erik Schokkaert, Director of the Center for Economics and Ethics, KULeuven
8. Notes from a traveler on the road to cell therapy in diabetes
Daniel Pipeleers, Director Diabetes Research Center Vrije Universiteit Brussel
9. Sharing responsibility in the discovery, development and delivery of medicines: A roundtable session about the actual challenges and potential added value of an industry in transition
Marleen Wynants, CROSSTALKS Operational Director
10. Why health care systems are not patient-centered and what this means
Max Baumann, Co-founder and member of the Board of Dialog Ethik (Interdisciplinary Institute for Health Care Ethics/Zurich)
11. Physicians and the pharmaceutical industry: A sensitive issue
Marc Bogaert, Professor Emeritus and former Dean of the Faculty of Medicine of UGent

PART THREE: NEW FRONTIERS

12. Common goals to guarantee accessible health care:
A potential win-win situation or just a (bad) dream?
Guy Peeters, General Secretary of the National Association of Socialist Mutualities
13. Co-payment and future socio-fiscal models
Orvill Adams & Vern Hicks, Orvill Adams & Associates
14. Why we need a new approach to pharmaceutical innovation:
A pragmatic answer to a moral question
Thomas Pogge, Professor of Philosophy and International Affairs at Yale University and Research Director at the Centre for the Study of Mind in Nature, University of Oslo & Doris Schroeder, Head of Centre and Professor of Moral Philosophy, Centre for Professional Ethics, University of Central Lancashire
15. Challenges and opportunities of cancer clinical research at
pan-European level
Françoise Meunier, Director General of EORTC, European Organisation for Research and Treatment of Cancer
16. Open source drug discovery: The Tropical Disease Initiative
Sara Engelen, CROSSTALKS Production Assistant & Marc A. Marti-Renom, Head of the Structural Genomics Unit of the Bioinformatics Department, Prince Felipe Research Center

Epilogue

Cradle to Grave
Susie Freeman, David Critchley & Liz Lee

List of pictures
Index